Press Releases

MGEN $2.82 $ - 0.07 (2.42%)

Press Releases

Search Press Releases
  
Subscribe for Email Alerts
5/8/2019
4:01 PM ET
Earnings Release

miRagen Announces First Quarter 2019 Financial Results and Provides Corporate Update

5/8/2019

Initiated patient dosing in the SOLAR Phase 2 trial for cobomarsen Released updated clinical data from the Phase 1 trial of cobomarsen in ATLL patientsReleased data from preclinical studies showing th...

 Continue Reading
4/29/2019
7:00 AM ET
Press Release

miRagen Therapeutics Announces New Data Supporting the Potential Use of Remlarsen to Prevent Corneal Fibrosis at the 2019 ARVO Meeting

4/29/2019

Preclinical data indicate that remlarsen accelerated the healing of corneal injury when compared to placebomiRagen believes the study’s results support that remlarsen may offer a novel therapeutic for...

 Continue Reading
4/26/2019
7:00 AM ET
Press Release

miRagen Announces New Clinical Data for Cobomarsen in ATLL Patients at the 19th Annual HTLV Congress in Lima, Peru

4/26/2019

Continued evidence of disease stabilization observed in ATLL patients treated with cobomarsen for up to 16 monthsCobomarsen allowed for rapid bone marrow recovery following chemotherapyIn most patient...

 Continue Reading
4/25/2019
8:00 AM ET
Press Release

miRagen Therapeutics to Report First Quarter 2019 Financial Results and Host a Conference Call on May 8th

4/25/2019

BOULDER, Colo., April 25, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted ther...

 Continue Reading
3/13/2019
4:05 PM ET
Earnings Release

miRagen Announces Fourth Quarter and Full Year 2018 Financial Results and Provides 2019 Outlook

3/13/2019

Cobomarsen tested in clinical trials for three different types of blood cancersMultiple clinical sites open and actively recruiting in the global Phase 2 SOLAR clinical trial of cobomarsen in CTCLData...

 Continue Reading
Displaying 1 to 5 (of 76 releases)